Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
Summary
In adults with type 2 diabetes on basal insulin, adding once-weekly fixed-dose cagrilintide–semaglutide (2.4 mg or 1.0 mg each) met the primary endpoint with statistically significant and clinically meaningful HbA1c reduction versus placebo. Weight also improved, addressing two key shortcomings of basal insulin regimens.
Key Findings
- Randomized, double-blind, multicenter phase 3 study (n=274) compared CagriSema (2.4 mg or 1.0 mg each) versus placebo added to basal insulin.
- Both CagriSema doses met the primary endpoint with statistically significant and clinically relevant HbA1c reductions versus placebo.
- Body weight decreased with CagriSema, addressing weight gain commonly seen with basal insulin regimens.
Clinical Implications
For patients inadequately controlled on basal insulin, adding CagriSema may reduce HbA1c and weight, potentially lowering insulin requirements and mitigating weight gain; clinicians should monitor for typical incretin-related gastrointestinal effects.
Why It Matters
Provides phase 3 evidence that an amylin–GLP-1 fixed-dose combination improves glycemia and weight when added to basal insulin, informing treatment intensification pathways beyond insulin up-titration.
Limitations
- Abstract does not provide detailed hypoglycemia rates or full safety profile
- Moderate sample size limits subgroup analyses
Future Directions
Define hypoglycemia risk, insulin dose adjustments, and long-term cardiovascular and renal outcomes; compare against GLP-1/GIP or other incretin combinations.
Study Information
- Study Type
- RCT
- Research Domain
- Treatment
- Evidence Level
- I - Double-blind, placebo-controlled, multicenter phase 3 randomized trial
- Study Design
- OTHER